RxDoctor Payments Data

Chadi Nouneh, MD

Cardiovascular Disease · Evergreen Park, ILNPI 1922100403

Payments from drug & device makers

$28,343in general payments, 2019–2025

Across 659 payments — averaging $43.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$14K
  • Philips North America LLC$2K
  • Johnson & Johnson$1K
  • Cardiva Medical, Inc.$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$991
  • plus $8K from 42 others

What the payments were for

  • Speaking & faculty fees$13,00046%
  • Travel & lodging$3,25811%
  • Food & beverage$12,02242%
  • Education$630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,343 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$1,024,257
Medicare patients
1,458
Services billed
10,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban394$406,383
EntrestoSacubitril/Valsartan221$237,073
JardianceEmpagliflozin103$107,810
XareltoRivaroxaban75$84,184
Repatha SureclickEvolocumab51$39,040
FarxigaDapagliflozin Propanediol43$36,803
BrilintaTicagrelor41$34,094
Metoprolol Succinate769$10,824
Atorvastatin Calcium517$6,353
Losartan Potassium477$4,729
Rosuvastatin Calcium312$3,970
Amlodipine Besylate464$3,903
Ranolazine ErRanolazine17$3,790
ClopidogrelClopidogrel Bisulfate290$3,287
Nifedipine ErNifedipine86$2,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$880$406,383394 claims
NovartisEntresto$945$237,073221 claims
Boehringer IngelheimJardiance$1,106$107,810103 claims
Johnson & JohnsonXarelto$1,195$84,18475 claims
AstraZenecaFarxiga, Brilinta$991$70,89684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Evergreen Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →